Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q1 2020 · 10-Q
Revenue$1.75K$1.75K−46.9% vs Q1 2019 Net Income-$5.14M-$5.14MN/M vs Q1 2019 EPS Diluted-$0.04-$0.04N/M vs Q1 2019 Operating Income-$815,856N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
Margins · derivedOperating margin-46514.0%−26898.6 pt vs Q1 2019
Net margin-293169.6%−273321.7 pt vs Q1 2019
ended Nov 30, 2019 · filed Jan 14, 2020 · 45 d after period end